Correction: Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors (PLoS ONE (2013) 8:12 (e81393) DOI: 10.1371/journal.pone.0081393);Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Choi, Yun Jung ^a   Park, Gun Min ^b   Rho, Jin Kyung ^a   Kim, Sun Ye ^a   So, Gwang Sup ^a   Kim, Hyeong Ryul ^a   Choi, Chang Min ^a   Lee, Jae Cheol ^a  

^a University of Ulsan   (South Korea)

^b Daehan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; SOMATOMEDIN BINDING PROTEIN 3; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MUTANT; CHEMOSENSITIVITY; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891942109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0213984     Document Type: Erratum

References (32)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factorrelated peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
2. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174.
3. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500. (Pubitemid 38720929)
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139. (Pubitemid 38637993)
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311. (Pubitemid 39209661)
6. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin Oncol 23:2513-2520. (Pubitemid 47050841)
7. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, et al. (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-smallcell lung cancer patients treated with gefitinib. J. Clin Oncol 23:2493-2501. (Pubitemid 47050839)
8. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, et al. (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin Oncol 23:6829-6837.
9. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655. (Pubitemid 40812628)
10. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98:1817-1824. (Pubitemid 350002184)
11. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792. (Pubitemid 40271173)
12. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73.
13. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 12:5764-5769. (Pubitemid 44629607)
14. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26.
15. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. (Pubitemid 46799492)
16. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937.
17. Zhang Z, Lee JC, Lin L, Olivas V, Au V, et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44:852-860.
18. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, et al. (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 118:2609-2619. (Pubitemid 351949788)
19. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34.
20. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, et al. (1999) Plasma levels of insulinlike growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-1516.
21. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, et al. (2002) Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res. 62:3530-3537. (Pubitemid 34651404)
22. Rosenzweig SA, Atreya HS (2010) Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80:1115-1124.
23. Dziadziuszko R, Camidge DR, Hirsch FR (2008) The insulin-like growth factor pathway in lung cancer. J Thorac Oncol; 3:815-818.
24. Grimberg A., Cohen P (2000) Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183:1-9. (Pubitemid 30130219)
25. Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, et al. (2010) Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother Pharmacol 66:381-388.
26. Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, et al. (2004) Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 64:7711-7723. (Pubitemid 39446902)
27. Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, et al. (2002) Clinical significance of insulin-like growth factorbinding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8:3796-3802. (Pubitemid 35424772)
28. Chang YS, Wang L, Liu D, Mao L, Hong WK, et al. (2002) Correlation between insulin-like growth factor binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8:3669-3675. (Pubitemid 35424756)
29. Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, et al. (2012) Expressions of Insulin-Like Growth Factor Receptor-1 and Insulin-Like Growth Factor Binding Protein 3 in Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer 13:385-390.
30. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, et al. (2011) Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer Oncol Rep 26:795-803.
31. Zimmermann EM, Li L, Hoyt EC, Pucilowska JB, Lichtman S, et al. (2000) Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. Am J Physiol Gastrointest Liver Physiol 278:G447-G457. (Pubitemid 30152491)
32. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, et al. (2009) The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res 7:1736-1743.